$GLAND ma reported a robust performance in the April-June quarter, with consolidated net profit rising 47.1% year-on-year to Rs 317 crore from Rs 215 crore. Revenue grew 19.6% to Rs 1,800.2 crore, while EBITDA climbed 33.1% to Rs 489.2 crore. Profit after tax margin expanded by around 330 basis points, reflecting improved operational efficiency. The strong numbers triggered a sharp market reaction. Shares of Gland Pharma jumped nearly 12%, emerging as the top midcap gainer. Brokerage firm Jefferies upgraded the stock to Buy, citing the solid quarter and positive outlook. The results highlight healthy growth in the company’s core injectable and complex generics business, boosting investor confidence amid a challenging pharmaceutical landscape.

#StockInNews#WatchOutFor

692 likes·59 comments